The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.00 (0.00%)
Spread: 1.48 (26.812%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 6.20
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tuesday broker round-up UPDATE

Tue, 21st Oct 2014 08:50

African Barrick Gold: JP Morgan cuts target price from 340p to 300p and stays with its overweight rating.Anglo American: JP Morgan raises target price from 1240p to 1310p, while leaving its underweight rating unchanged. Investec increases target price from 1573p to 1603p and stays with its buy recommendation.Antofagasta: JP Morgan reduces target price from 830p to 760p maintaining a neutral rating.BHP Billiton: JP Morgan reduces target price from 2250p to 2180p keeping a neutral rating.Brooks Macdonald: Numis reduces target price from 1550p to 1470p retaining its hold recommendation.Brown (N) Group: Credit Suisse reduces target price from 518p to 330p downgrading to neutral.BT Group: Goldman Sachs cuts target price from 620p to 600p retaining a strong buy recommendation.Cable & Wireless Communications: JP Morgan lowers target price from 53p to 50p and maintains a neutral rating.Dairy Crest: UBS cuts target price from 460p to 410p retaining a neutral rating.Devro: N+1 Singer upgrades from hold to buy with a target price of 257p.Dialight: Investec upgrades from sell to hold with a target price of 850p.GKN: JP Morgan reduces target price from 460p to 370p reiterating its overweight rating.Go Ahead Group: Investec increases target price from 2670p to 2750p and leaves its buy recommendation unchanged.Hellermann Tyton: UBS initiates with a target price of 300p and a neutral rating.Hochschild Mining: JP Morgan cuts target price from 185p to 150p keeping its neutral rating.Informa: Westhouse Securities upgrades from neutral to buy with a target price of 554p.Inmarsat: JP Morgan ups target price from 810p to 840p and reiterates an overweight rating.Kazakhmys: JP Morgan cuts target price from 400p to 375p and stays with its overweight rating.Lloyds Banking Group: Credit Suisse shifts target price from 68p to 72p and stays with its neutral rating.NMC Health: Investec initiates with a target price of 610p and a buy recommendation.Petropavlovsk: JP Morgan lowers target price from 20p to 10p and reiterates an underweight rating.President Energy: Canaccord Genuity moves target price from 50p to 60p and retains its speculative buy recommendation.Redefine: Deutsche Bank lowers target price from 56p to 53p keeping its hold recommendation.Rightmove: Credit Suisse reduces target price from 3100p to 2655p and reiterates an outperform rating.Standard Chartered: Credit Suisse reduces target price from 1150p to 1020p and maintains an underperform rating.Synairgen: N+1 Singer initiates with a target price of 49p and a buy recommendation.Talk Talk Telecom: Goldman Sachs cuts target price from 450p to 435p and maintains a buy recommendation.Telecity Group: JP Morgan ups target price from 900p to 925p and keeps an overweight rating.Travis Perkins: UBS reduces target price from 2100p to 2000p reiterating a buy recommendation. Deutsche Bank lowers target price from 1901p to 1898p and keeps its hold recommendation.Vedanta Resources: JP Morgan reduces target price from 1130p to 1030p and retains a neutral rating.William Hill: Canaccord Genuity moves target price from 350p to 365p and keeps a hold recommendation.Zoopla Property: Credit Suisse cuts target price from 290p to 270p leaving its outperform rating unaltered.
More News
8 Sep 2020 19:32

IN BRIEF: Synairgen Reports Promising Findings From SNG001 Trial

IN BRIEF: Synairgen Reports Promising Findings From SNG001 Trial

Read more
8 Sep 2020 15:16

Synairgen upbeat on latest data from SNG001 trials

(Sharecast News) - Respiratory drug discovery and development company Synairgen announced positive data from the interim analysis of its exploratory phase 2 clinical trial of inhaled 'SNG001' on Tuesday, in chronic obstructive pulmonary disease (COPD) patients with a confirmed respiratory viral infection.

Read more
21 Jul 2020 15:51

IN BRIEF: Synairgen Moving "Rapidly" To Get SNG001 Over Line

IN BRIEF: Synairgen Moving "Rapidly" To Get SNG001 Over Line

Read more
20 Jul 2020 20:23

COVID SCIENCE-Multiple vaccine candidates show early promise; inhaled interferon helps severe COVID-19 patients

By Nancy LapidJuly 20 (Reuters) - The following is a brief roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.Early tests of COVID-19 ...

Read more
20 Jul 2020 16:55

LONDON MARKET CLOSE: FTSE 100 Lags Despite Encouraging Vaccine News

LONDON MARKET CLOSE: FTSE 100 Lags Despite Encouraging Vaccine News

Read more
20 Jul 2020 11:54

Synairgen Shares Soar On Positive Trial Results For Covid-19 Treatment

Synairgen Shares Soar On Positive Trial Results For Covid-19 Treatment

Read more
20 Jul 2020 09:10

REFILE-UPDATE 2-Synairgen soars after drug shows promise in COVID-19 cases

(Refiles to correct spelling in the media identifier)* Shares hit all-time high on Monday* Company's drug cuts risk of severe COVID-19 by 79%* Some researchers caution on enthusiasmBy Aakash BJuly 20 (Reuters) - Synairgen shares rose almost sixfold ...

Read more
20 Jul 2020 09:10

UPDATE 2-Synairgen soars after drug shows promise in COVID-19 cases

* Shares hit all-time high on Monday* Company's drug cuts risk of severe COVID-19 by 79%* Some researchers caution on enthusiasm (Recasts, adds comment from CEO and academic expert)By Aakash BJuly 20 (Reuters) - Synairgen shares rose almost sixfold...

Read more
20 Jul 2020 09:10

UPDATE 1-Synairgen shares soar as drug shows lower risk of severe COVID-19 cases

(Adds details on the trial, shares)July 20 (Reuters) - Synairgen Plc said on Monday its drug helped reduce the risk of severe cases in hospitalised patients with COVID-19, according to data from a trial of more than 100 people in the United Kingdo...

Read more
20 Jul 2020 07:56

Europe open: Stocks reverse early losses, healthcare leads

(Sharecast News) - Stocks have recovered from early selling following news that European Union leaders meeting in Brussels had made progress on the terms for a reconstruction fund.

Read more
20 Jul 2020 07:56

Synairgen's drug shows reduced risk of severe disease in COVID-19 patients

July 20 (Reuters) - Synairgen Plc said on Monday its drug helped reduce the risk of developing severe diseases in hospitalised COVID-19 patients, according to data from a trial of more than 100 people in the United Kingdom.The trial, which used in...

Read more
20 Jul 2020 07:20

Synairgen treatment reduces risk of 'severe' Covid-19 by 79%

(Sharecast News) - Synairgen's Covid-19 treatment sharply reduced the risk of patients developing severe forms of the illness provoked by the novel coronavirus, clinical trials showed.

Read more
22 Jun 2020 16:09

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
18 Jun 2020 17:59

IN BRIEF: Synairgen Expands Home Setting Trial Of Inhaled SNG001

IN BRIEF: Synairgen Expands Home Setting Trial Of Inhaled SNG001

Read more
18 Jun 2020 09:12

Synairgen expands Covid-19 trial nationwide

(Sharecast News) - Synairgen is to expand trials of a potential treatment for Covid-19 nationally, the respiratory drug specialist said on Thursday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.